GADICKE ANSBERT
SEC CIK 1134655 · EDGAR
BoughtSold
Most active insiders at AKTS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | NODELMAN OLEG | Dir | $40.00M | — |
| 2 | MPM ONCOLOGY INNOVATIONS FUND LP | 10% | $20.03M | — |
| 3 | GADICKE ANSBERT | 10% | $20.03M | — |
| 4 | VIDA VENTURES II-A, LLC | 10% | $15.03M | — |
| 5 | Kim Helen Susan | Dir, 10% | $15.03M | — |
| 6 | Foley Todd | Dir, 10% | $4.19M | — |
| 7 | Czibere Akos | Chief Medical Off | — | $1.65M |
| 8 | Ron-Bigger Shulamit | COO | — | $1.39M |
| 9 | Herrmann Ken | Dir | — | $196.5K |
| 10 | Segal Lloyd Mitchell | Dir | — | — |
Transactions 19
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2026-01-14 | 2026-01-12 | AKTS | Aktis Oncology, Inc. | GADICKE ANSBERT | 10% | C - Cnv Deriv | — | +8.81M | 7.57M | New | — |
| DI | 2026-01-14 | 2026-01-12 | AKTS | Aktis Oncology, Inc. | GADICKE ANSBERT | 10% | P - Purchase | $18.00 | +1.11M | 10.26M | +12% | +$20.03M |
| I | 2022-08-01 | 2022-07-28 | KLRS | Kalaris Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | A - Grant | $4.61 | +3.25M | 16.67M | +24% | +$15.00M |
| I | 2021-09-20 | 2021-09-16 | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.06 | -3,124 | 7.65M | -0.0% | -$90.8K |
| 2021-09-20 | 2021-09-16 | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.06 | -432 | 244.6K | -0.2% | -$12.6K | |
| MI | 2021-09-16 | 2021-09-14+ | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.17 | -13.5K | 7.66M | -0.2% | -$394.6K |
| M | 2021-09-16 | 2021-09-14+ | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.17 | -1,870 | 245.0K | -0.8% | -$54.5K |
| MI | 2021-09-13 | 2021-09-09+ | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.23 | -23.3K | 7.67M | -0.3% | -$679.7K |
| M | 2021-09-13 | 2021-09-09+ | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.23 | -3,215 | 247.3K | -1% | -$94.0K |
| MI | 2021-09-08 | 2021-09-03+ | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.20 | -48.6K | 7.70M | -0.6% | -$1.42M |
| M | 2021-09-08 | 2021-09-03+ | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.20 | -6,724 | 250.1K | -3% | -$196.4K |
| MI | 2021-09-02 | 2021-08-31+ | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.50 | -24.3K | 7.74M | -0.3% | -$717.2K |
| M | 2021-09-02 | 2021-08-31+ | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.50 | -3,360 | 259.0K | -1% | -$99.1K |
| M | 2021-08-31 | 2021-08-27+ | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.24 | -6,131 | 260.2K | -2% | -$179.3K |
| MI | 2021-08-31 | 2021-08-27+ | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.24 | -44.4K | 7.76M | -0.6% | -$1.30M |
| MI | 2021-08-25 | 2021-08-23+ | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.29 | -106.0K | 7.86M | -1% | -$3.10M |
| M | 2021-08-25 | 2021-08-23+ | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.29 | -14.6K | 266.5K | -5% | -$428.7K |
| I | 2021-08-12 | 2021-08-11 | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.05 | -2,510 | 7.91M | -0.0% | -$72.9K |
| 2021-08-12 | 2021-08-11 | CGEM | Cullinan Therapeutics, Inc. | GADICKE ANSBERT | Dir, 10% | S - Sale | $29.05 | -347 | 280.9K | -0.1% | -$10.1K |
Purchase Sale Sale after option exercise All abbreviations